Ther­mo Fish­er forges $1.7 bil­lion deal to buy a con­tract play­er in the boom­ing gene ther­a­py field

Ther­mo Fish­er is snap­ping up one of the new­born con­tract play­ers in the bur­geon­ing gene ther­a­py field.

The com­pa­ny an­nounced late Sun­day night that they are buy­ing Bram­mer Bio — which han­dles con­tract vi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py de­vel­op­ers — for $1.7 bil­lion.

Gene ther­a­pies may be just at the be­gin­ning stages of com­mer­cial­iza­tion, but a host of new pro­grams has be­gun to at­tract the ma­jors in a slate of buy­out deals, topped by Roche’s $4.3 bil­lion deal to ac­quire Spark. Be­hind that you’ll find a group of out­sourc­ing com­pa­nies of­fer­ing the tech and man­u­fac­tur­ing know-how to do much of the work un­der con­tract, which is where Ther­mo Fish­er is po­si­tion­ing it­self now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.